The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. LONDON (AP) — The ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

Needham upgraded Gilead Sciences (NASDAQ:GILD) to Buy from Hold on Friday, citing a physical survey to suggest that the ...

Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

FDA approves powerful HIV drug that nearly eliminated spread in clinical trials The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to ...

European regulators have greenlit a twice-yearly injection to prevent HIV that has been hailed as a game-changer in the ...

The U.S. Food and Drug Administration (FDA) has approved the first-ever long-acting injectable drug for HIV prevention.. Until this week, the only FDA-licensed and approved medications for HIV pre ...

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.